119 related articles for article (PubMed ID: 11056237)
1. Effects of functional ovarian cysts detected on the 7th day of gonadotropin-releasing hormone analog administration on the outcome of IVF treatment.
Biljan MM; Lapensée L; Mahutte NG; Bissonnette F; Hemmings R; Tan SL
Fertil Steril; 2000 Nov; 74(5):941-5. PubMed ID: 11056237
[TBL] [Abstract][Full Text] [Related]
2. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
J Assist Reprod Genet; 1998 Nov; 15(10):599-604. PubMed ID: 9866068
[TBL] [Abstract][Full Text] [Related]
4. The significance of delayed suppression using buserelin acetate and recombinant follicle-stimulating hormone in a long protocol in vitro fertilization program.
Ravhon A; Aurell R; Lawrie H; Margara R; Winston RM
Fertil Steril; 2000 Feb; 73(2):325-9. PubMed ID: 10685537
[TBL] [Abstract][Full Text] [Related]
5. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection.
Takeuchi S; Minoura H; Shibahara T; Tsuiki Y; Noritaka F; Toyoda N
Fertil Steril; 2001 Sep; 76(3):532-7. PubMed ID: 11532477
[TBL] [Abstract][Full Text] [Related]
6. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.
Albano C; Felberbaum RE; Smitz J; Riethmüller-Winzen H; Engel J; Diedrich K; Devroey P
Hum Reprod; 2000 Mar; 15(3):526-31. PubMed ID: 10686191
[TBL] [Abstract][Full Text] [Related]
7. Pituitary suppression in ultrasound-monitored frozen embryo replacement cycles. A randomised study.
El-Toukhy T; Taylor A; Khalaf Y; Al-Darazi K; Rowell P; Seed P; Braude P
Hum Reprod; 2004 Apr; 19(4):874-9. PubMed ID: 15016780
[TBL] [Abstract][Full Text] [Related]
8. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
[TBL] [Abstract][Full Text] [Related]
9. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
Borm G; Mannaerts B
Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
[TBL] [Abstract][Full Text] [Related]
10. Progestogen therapy during pituitary desensitization with gonadotropin-releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study.
Engmann L; Maconochie N; Bekir J; Tan SL
Am J Obstet Gynecol; 1999 Sep; 181(3):576-82. PubMed ID: 10486466
[TBL] [Abstract][Full Text] [Related]
11. Comparative study on the pregnancy outcomes of in vitro fertilization-embryo transfer between long-acting gonadotropin-releasing hormone agonist combined with transvaginal ultrasound-guided cyst aspiration and long-acting gonadotropin-releasing hormone agonist alone.
Guo YH; Lu N; Zhang Y; Su YC; Wang Y; Zhang YL; Sun YP
Contemp Clin Trials; 2012 Nov; 33(6):1206-10. PubMed ID: 22820320
[TBL] [Abstract][Full Text] [Related]
12. Impact of baseline cysts at the time of administration of gonadotropin-releasing hormone analog for in vitro fertilization.
Zeyneloglu HB; Isik AZ; Kara S; Senöz S; Ozcan U; Gökmen O
Int J Fertil Womens Med; 1998; 43(6):300-5. PubMed ID: 9920539
[TBL] [Abstract][Full Text] [Related]
13. Follicle cyst formation after administration of different gonadotrophin-releasing hormone analogues for assisted reproduction.
Tarlatzis BC; Bili H; Bontis J; Lagos S; Vatev I; Mantalenakis S
Hum Reprod; 1994 Nov; 9(11):1983-6. PubMed ID: 7868660
[TBL] [Abstract][Full Text] [Related]
14. A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study.
Dada T; Salha O; Baillie HS; Sharma V
Hum Reprod; 1999 Feb; 14(2):288-93. PubMed ID: 10099965
[TBL] [Abstract][Full Text] [Related]
15. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial.
Cheung LP; Lam PM; Lok IH; Chiu TT; Yeung SY; Tjer CC; Haines CJ
Hum Reprod; 2005 Mar; 20(3):616-21. PubMed ID: 15608037
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cyst formation: a complication of gonadotropin-releasing hormone agonist therapy.
Feldberg D; Ashkenazi J; Dicker D; Yeshaya A; Goldman GA; Dicker D; Goldman JA
Fertil Steril; 1989 Jan; 51(1):42-5. PubMed ID: 2521325
[TBL] [Abstract][Full Text] [Related]
17. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles.
Albuquerque LE; Saconato H; Maciel MC
Cochrane Database Syst Rev; 2002; (3):CD002808. PubMed ID: 12137658
[TBL] [Abstract][Full Text] [Related]
18. Influence of ovarian cysts on the results of in vitro fertilization.
Parinaud J; Cohen K; Oustry P; Perineau M; Monroziès X; Rème JM
Fertil Steril; 1992 Dec; 58(6):1174-7. PubMed ID: 1459269
[TBL] [Abstract][Full Text] [Related]
19. Follicular development and hormonal levels following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women undergoing ovarian stimulation after pituitary suppression for in vitro fertilization: implications for implantation potential.
Balasch J; Fábregues F; Creus M; Peñarrubia J; Vidal E; Carmona F; Puerto B; Vanrell JA
J Assist Reprod Genet; 2000 Jan; 17(1):20-7. PubMed ID: 10754779
[TBL] [Abstract][Full Text] [Related]
20. Development of ovarian cysts during gonadotrophin-releasing hormone agonists (GnRHa) administration.
Sampaio M; Serra V; Miro F; Calatayud C; Castellvi RM; Pellicer A
Hum Reprod; 1991 Feb; 6(2):194-7. PubMed ID: 1905307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
